33 research outputs found

    A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression

    Get PDF
    Background Patients with chronic forms of major depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain. Methods We randomly assigned 681 adults with a chronic nonpsychotic major depressive disorder to 12 weeks of outpatient treatment with nefazodone (maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20 sessions), or both. At base line, all patients had scores of at least 20 on the 24-item Hamilton Rating Scale for Depression (indicating clinically significant depression). Remission was defined as a score of 8 or less at weeks 10 and 12. For patients who did not have remission, a satisfactory response was defined as a reduction in the score by at least 50 percent from base line and a score of 15 or less. Raters were unaware of the patients’ treatment assignments. Results Of the 681 patients, 662 attended at least one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in both the nefazodone group and the psychotherapy group, as compared with 73 percent in the combined-treatment group (P Conclusions Although about half of patients with chronic forms of major depression have a response to short-term treatment with either nefazodone or a cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more efficacious than either treatment alone

    Meta-cognitive beliefs about worry and pain catastrophising as mediators between neuroticism and pain behaviour

    Get PDF
    © 2015 The Australian Psychological SocietyBackground: The present study explored the relationship between neuroticism, meta-cognitive beliefs about worry, pain catastrophising, and pain behaviour. Methods: A non-clinical convenience sample of 308 participants completed the following four measures in this cross-sectional study: Neo Five-Factor Inventory, Meta-Cognitions Questionnaire 30, Pain Catastrophising Scale, and the Pain Behaviour Checklist. Results: A multiple-step multiple mediator analysis was employed to test a model in which (1) positive meta-cognitive beliefs about worry would mediate the relationship between neuroticism and pain catastrophising and (2) negative meta-cognitive beliefs about worry would mediate the relationship between pain catastrophising and self-reported pain behaviour. We also hypothesised that the combined effects of meta-cognitive beliefs about worry and pain catastrophising on self-reported pain behaviour would be independent of neuroticism. Results supported the proposed structure with pain catastrophising and meta-cognitive beliefs about worry mediating fully the effect of neuroticism on self-reported pain behaviour. Conclusions: These findings identify, for the first time in the literature, a link between meta-cognitive beliefs about worry and both self-reported pain behaviour and pain catastrophising. The implications of these findings are discussed. This is an electronic version of an article published in Spada, MM and Gay, H and Nikčevic, AV and Fernie, BA and Caselli, G (2016) Meta-cognitive beliefs about worry and pain catastrophising as mediators between neuroticism and pain behaviour. Clinical Psychologist, 20 (3). pp. 138-146. DOI 10.1111/cp.1208

    Behavioral Activation and Inhibition Systems and the Severity and course of Depression

    No full text
    Theorists have proposed that depression is associated with abnormalities in the behavioral activation (BAS) and behavioral inhibition (BIS) systems. In particular, depressed individuals are hypothesized to exhibit deficient BAS and overactive BIS functioning. Self-reported levels of BAS and BIS were examined in 62 depressed participants and 27 nondepressed controls. Clinical functioning was assessed at intake and at 8-month follow-up. Relative to nondepressed controls, depressed participants reported lower BAS levels and higher BIS levels. Within the depressed group, lower BAS levels were associated with greater concurrent depression severity and predicted worse 8-month outcome. Levels of both BIS and BAS showed considerable stability over time and clinical state. Overall, results suggest that BAS dysregulation exacerbates the presentation and course of depressive illness

    Select comorbid personality disorders and the treatment of chronic depression with nefazodone, targeted psychotherapy, or their combination.

    No full text
    BACKGROUND: Individuals with chronic depression respond poorly to both medication and psychotherapy. The reasons for the poorer response, however, remain unclear. One potential factor is the presence of comorbid Axis II personality disorders (PDs), which occur at high rates among these patients. METHODS: This study examines the moderating influence of co-occurring PDs, primarily in cluster C, among 681 chronically depressed adult outpatients who were randomly assigned to 12 weeks of treatment with nefazodone, a specialized psychotherapy for chronic depression, or their combination. RESULTS: At baseline, 50.4% (n=343) of patients met criteria for one or more Axis II disorders. Following 12 weeks of treatment, patients with comorbid PDs had statistically lower depression scores (M=12.2, SD=+9.2) than patients without comorbid PDs (M=13.5, SD=+8.7). There was no differential impact of a comorbid PD on responsiveness to medication versus psychotherapy. The results did not change when the data were analyzed using an intent-to-treat sample or when individual personality disorders were examined separately. LIMITATIONS: Patients with severe borderline, antisocial, and schizotypal PDs were excluded from study entry; therefore, these data primarily apply to patients with cluster C PDs and may not generalize to other Axis II conditions. CONCLUSIONS: Comorbid Axis II disorders did not negatively affect treatment outcome and did not differentially affect response to psychotherapy versus medication. Treatment formulations for chronically depressed patients with certain PDs may not need to differ from treatment formulations of chronically depressed patients without co-occurring PDs
    corecore